NOVARTIS RADICALLY REMAKING ITS DRUG BUSINESS

摘要

Five neuroscientists file nervously into No-vartis' vast boardroom in Basel. CEO Daniel L. Vasella is seated at the table, along with nine senior executives that make up the company's innovation board. The scientists hope to persuade Vasella to move forward on an experimental vaccine for Alzheimer's disease, an illness that afflicts 25 million people worldwide. Even a moderately effective treat -ment would be a blockbuster, but testing the vaccine would take years and several hundred million dollars.